Unnamed: 0,title,date,stock,sentiment
225228.0,"ChemoCentryx Files For Mixed Offering, Size Not Disclosed",2020-06-10 16:05:00-04:00,CCXI,neutral
225229.0,ChemoCentryx Phase III ADVOCATE Trial Of Avacopan In ANCA-Associated Vasculitis Highlighted In Oral Plenary Presentations At EULAR And ERA-EDTA Congresses,2020-06-03 07:32:00-04:00,CCXI,neutral
225230.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,CCXI,positive
225231.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-28 10:39:00-04:00,CCXI,neutral
225232.0,"The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer",2020-05-28 08:24:00-04:00,CCXI,neutral
225233.0,"Benzinga's Top Upgrades, Downgrades For May 27, 2020",2020-05-27 09:35:00-04:00,CCXI,positive
225234.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,CCXI,positive
225235.0,"Wells Fargo Initiates Coverage On ChemoCentryx with Overweight Rating, Announces Price Target of $79",2020-05-27 06:56:00-04:00,CCXI,negative
225236.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,CCXI,neutral
225237.0,Stocks That Hit 52-Week Highs On Friday,2020-05-22 10:31:00-04:00,CCXI,neutral
225238.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,CCXI,neutral
225239.0,Stocks That Hit 52-Week Highs On Thursday,2020-05-21 10:25:00-04:00,CCXI,neutral
225240.0,"The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test",2020-05-20 08:12:00-04:00,CCXI,neutral
225241.0,"Canaccord Genuity Maintains Buy on ChemoCentryx, Lowers Price Target to $58",2020-05-19 11:35:00-04:00,CCXI,negative
225242.0,ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS),2020-05-18 08:33:00-04:00,CCXI,neutral
225243.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-18 07:34:00-04:00,CCXI,neutral
225244.0,"JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to $64",2020-05-14 09:19:00-04:00,CCXI,neutral
225245.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,CCXI,negative
225246.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,CCXI,neutral
225247.0,"Canaccord Genuity Maintains Buy on ChemoCentryx, Raises Price Target to $68",2020-05-12 12:20:00-04:00,CCXI,neutral
225248.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,CCXI,neutral
225249.0,ChemoCentryx shares are trading higher after the company reported Q1 earnings results.,2020-05-12 08:55:00-04:00,CCXI,positive
225250.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,CCXI,negative
225251.0,10 Biggest Price Target Changes For Tuesday,2020-05-12 08:03:00-04:00,CCXI,neutral
225252.0,"Raymond James Reiterates Strong Buy on ChemoCentryx, Raises Price Target to $102",2020-05-12 07:27:00-04:00,CCXI,positive
225253.0,"SVB Leerink Reiterates Outperform on ChemoCentryx, Raises Price Target to $65",2020-05-12 06:37:00-04:00,CCXI,neutral
225254.0,"ChemoCentryx Q1 EPS $(0.350) Misses $(0.300) Estimate, Sales $6.008M Miss $8.750M Estimate",2020-05-11 16:24:00-04:00,CCXI,negative
225255.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,CCXI,neutral
225256.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,CCXI,positive
225257.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,CCXI,neutral
225258.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,CCXI,positive
225259.0,Stocks That Hit 52-Week Highs On Monday,2020-05-04 10:35:00-04:00,CCXI,neutral
225260.0,"The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO",2020-05-01 07:54:00-04:00,CCXI,neutral
225261.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,CCXI,positive
225262.0,"JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to $61",2020-03-11 10:19:00-04:00,CCXI,neutral
225263.0,"Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $64",2020-03-11 07:17:00-04:00,CCXI,positive
225264.0,"ChemoCentryx Q4 EPS $(0.26), Inline, Sales $10M Beat $9.68M Estimate",2020-03-10 16:15:00-04:00,CCXI,neutral
225265.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,CCXI,negative
225266.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,CCXI,negative
225267.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,CCXI,negative
225268.0,"JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to $60",2020-02-18 08:24:00-05:00,CCXI,neutral
225269.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,CCXI,negative
225270.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,CCXI,negative
225271.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,CCXI,positive
225272.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,CCXI,neutral
225273.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,CCXI,positive
225274.0,Stocks That Hit 52-Week Highs On Monday,2020-02-10 10:25:00-05:00,CCXI,neutral
225275.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,CCXI,negative
225276.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,CCXI,neutral
225277.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,CCXI,negative
225278.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,CCXI,neutral
225279.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,CCXI,neutral
225280.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,CCXI,neutral
225281.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,CCXI,negative
225282.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,CCXI,neutral
225283.0,Shares of several healthcare companies are trading higher in sympathy with the overall market on a rebound after increased fear of the Wuhan coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.,2020-02-03 11:13:00-05:00,CCXI,positive
225284.0,23 Biotechnology Stocks Moving In Monday's After-Market Session,2020-01-27 23:45:00-05:00,CCXI,neutral
225285.0,36 Healthcare Stocks Moving In Monday's After-Market Session,2020-01-27 23:41:00-05:00,CCXI,neutral
225286.0,10 Biggest Price Target Changes For Friday,2020-01-24 08:55:00-05:00,CCXI,neutral
225287.0,"H.C. Wainwright Maintains Buy on ChemoCentryx, Raises Price Target to $60",2020-01-24 07:39:00-05:00,CCXI,neutral
225288.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,CCXI,neutral
225289.0,ChemoCentryx shares are trading lower. Not currently seeing any company-specific news.,2020-01-23 11:15:00-05:00,CCXI,neutral
225290.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,CCXI,neutral
225291.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,CCXI,neutral
225292.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,CCXI,neutral
225293.0,ChemoCentryx shares are trading higher on continued momentum after the company held its presentation at the JP Morgan Healthcare Conference on Tuesday.,2020-01-17 11:46:00-05:00,CCXI,positive
225294.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,CCXI,negative
225295.0,ChemoCentryx shares are trading higher following yesterday's presentation at the JP Morgan Healthcare Conference.,2020-01-16 11:11:00-05:00,CCXI,positive
225296.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,CCXI,neutral
225297.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,CCXI,negative
225298.0,﻿ChemoCentryx shares are trading lower. Not seeing any company-specific news to justify the price action.,2020-01-02 11:26:00-05:00,CCXI,neutral
225299.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,CCXI,negative
225300.0,ChemoCentryx shares are trading higher. Not seeing any news to justify the price action.,2019-12-30 13:09:00-05:00,CCXI,positive
225301.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,CCXI,negative
225302.0,ChemoCentryx shares are trading higher. Not currently seeing any company-specific news.,2019-12-16 14:02:00-05:00,CCXI,positive
225303.0,ChemoCentryx shares are trading higher in sympathy with the overall market amid positive US-China trade developments which have caused US equities across many sectors to trade higher.,2019-12-12 11:22:00-05:00,CCXI,positive
225304.0,There's A Really Good Chance You Missed One Of The Year's Best ETFs,2019-12-09 07:25:00-05:00,CCXI,positive
225305.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,CCXI,neutral
225306.0,ChemoCentryx shares are trading higher. Not currently seeing any company-specific news.,2019-12-05 14:45:00-05:00,CCXI,positive
225307.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,CCXI,neutral
225308.0,"The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen",2019-11-27 07:26:00-05:00,CCXI,negative
225309.0,60 Biggest Movers From Yesterday,2019-11-27 05:03:00-05:00,CCXI,neutral
225310.0,Mid-Afternoon Market Update: Dick's Sporting Goods Jumps On Earnings Beat; Dollar Tree Shares Plunge,2019-11-26 14:30:00-05:00,CCXI,positive
225311.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-11-26 12:09:00-05:00,CCXI,neutral
225312.0,Mid-Day Market Update: Movado Falls Following Downbeat Q3 Results; ChemoCentryx Shares Surge,2019-11-26 12:00:00-05:00,CCXI,positive
225313.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-26 11:03:00-05:00,CCXI,neutral
225314.0,ChemoCentryx Stock More Than Triples On Late-Stage Readout For Rare Inflammatory Disease Drug,2019-11-26 10:20:00-05:00,CCXI,neutral
225315.0,Mid-Morning Market Update: Markets Edge Higher; Best Buy Profit Tops Expectations,2019-11-26 10:18:00-05:00,CCXI,positive
225316.0,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Nov. 26, 2019: BBY, CCXI, PANW, DLTR, DE",2019-11-26 08:42:00-05:00,CCXI,positive
225317.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,CCXI,positive
225318.0,14 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-26 07:58:00-05:00,CCXI,neutral
225319.0,24 Stocks Moving in Tuesday's Pre-Market Session,2019-11-26 07:55:00-05:00,CCXI,neutral
225320.0,"Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $56",2019-11-26 07:42:00-05:00,CCXI,positive
225321.0,ChemoCentryx shares are trading higher after the company announced the pivotal phase-III ADVOCATE trial of avacopan for the treatment of patients with ANCA-associated vasculitis met both primary endpoints.,2019-11-26 07:35:00-05:00,CCXI,positive
225322.0,VFMCRP and ChemoCentryx Announce Positive Topline Data From Pivotal Phase-III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA Associated Vasculitis,2019-11-26 03:28:00-05:00,CCXI,positive
225323.0,ChemoCentryx To Resume Trade At 4:35 p.m. ET,2019-11-25 16:09:00-05:00,CCXI,neutral
225324.0,ChemoCentryx Reports Topline Data From Pivotal Phase 3 ADVOCATE Trial Met Both Primary Endpoints,2019-11-25 16:09:00-05:00,CCXI,neutral
225325.0,ChemoCentryx Shares Halted News Pending,2019-11-25 16:00:00-05:00,CCXI,positive
225326.0,ChemoCentryx Option Alert: Dec 20 $10 Calls at the Ask: 3000 @ $2.451 vs 4676 OI; Ref=$8.745,2019-11-19 10:02:00-05:00,CCXI,positive
225327.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,CCXI,negative
225328.0,"ChemoCentryx Q3 EPS $(0.22) Beats $(0.28) Estimate, Sales $10.58M Beat $7.7M Estimate",2019-11-04 16:42:00-05:00,CCXI,neutral
225329.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2019",2019-09-12 09:32:00-04:00,CCXI,positive
225330.0,10 Biggest Price Target Changes For Thursday,2019-09-12 08:57:00-04:00,CCXI,neutral
225331.0,"JP Morgan Upgrades ChemoCentryx to Overweight, Lowers Price Target to $14",2019-09-12 06:24:00-04:00,CCXI,negative
225332.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,CCXI,neutral
225333.0,85 Biggest Movers From Yesterday,2019-08-07 05:39:00-04:00,CCXI,neutral
225334.0,68 Stocks Moving In Tuesday's Mid-Day Session,2019-08-06 13:55:00-04:00,CCXI,neutral
225335.0,Stocks That Broke Yearly Lows Tuesday Morning,2019-08-06 12:06:00-04:00,CCXI,negative
225336.0,ChemoCentryx shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.,2019-08-05 16:47:00-04:00,CCXI,neutral
225337.0,"ChemoCentryx Q2 EPS $(0.26) Misses $(0.22) Estimate, Sales $7.173M Miss $9.83M Estimate",2019-08-05 16:45:00-04:00,CCXI,negative
225338.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,CCXI,negative
225339.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,CCXI,neutral
225340.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,CCXI,positive
225341.0,10 Biggest Price Target Changes For Thursday,2019-06-06 09:58:00-04:00,CCXI,neutral
225342.0,"Raymond James Maintains Strong Buy on ChemoCentryx, Lowers Price Target to $17",2019-06-06 08:19:00-04:00,CCXI,positive
225343.0,"The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering",2019-06-06 07:37:00-04:00,CCXI,neutral
225344.0,66 Biggest Movers From Yesterday,2019-06-06 05:17:00-04:00,CCXI,neutral
225345.0,InflaRx Shares Slammed As Skin Inflammation Drug Flunks Midstage Trial; ChemoCentryx Moves In Sympathy,2019-06-05 13:40:00-04:00,CCXI,positive
225346.0,44 Stocks Moving In Wednesday's Mid-Day Session,2019-06-05 12:42:00-04:00,CCXI,neutral
225347.0,ChemoCentryx Shares Down 23% Wednesday Morning; JP Morgan Analyst Anupam Rama Tells Benzinga Stock Moving Given 'read-through from InflaRx trial set back',2019-06-05 10:29:00-04:00,CCXI,positive
225348.0,ChemoCentryx shares are trading lower in sympathy with InflaRx (IFRX) after the latter company announced failed results from its C5a inhibitor study.,2019-06-05 09:39:00-04:00,CCXI,negative
225349.0,ChemoCentryx S-3 Shows Registration For $200M Mixed Securities Offering,2019-05-07 15:47:00-04:00,CCXI,positive
225350.0,"Chemocentryx Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $8.33M Miss $10.97M Estimate",2019-05-06 16:08:00-04:00,CCXI,negative
225351.0,ChemoCentryx To Present At H.C. Wainwright Global Life Sciences Conference,2019-04-02 08:33:00-04:00,CCXI,neutral
225352.0,71 Biggest Movers From Yesterday,2019-03-28 05:01:00-04:00,CCXI,neutral
225353.0,60 Stocks Moving In Wednesday's Mid-Day Session,2019-03-27 13:08:00-04:00,CCXI,neutral
225354.0,ChemoCentryx shares are trading higher after B. Riley FBR upgraded the company's stock from Neutral to Buy and raised its price target from $12.50 to $22 per share.,2019-03-27 10:39:00-04:00,CCXI,positive
225355.0,10 Biggest Price Target Changes For Wednesday,2019-03-27 09:44:00-04:00,CCXI,neutral
225356.0,"Benzinga's Top Upgrades, Downgrades For March 27, 2019",2019-03-27 09:17:00-04:00,CCXI,positive
225357.0,"B. Riley FBR Upgrades ChemoCentryx to Buy, Raises Price Target to $22",2019-03-27 06:34:00-04:00,CCXI,neutral
225358.0,"On March 25, 2019, ChemoCentryx Sold ~4.82M Shares of Common Stock Pursuant to Equity Distribution Agreement with Piper Jaffray @11.40/Share",2019-03-26 06:14:00-04:00,CCXI,positive
225359.0,52 Biggest Movers From Yesterday,2019-03-26 05:04:00-04:00,CCXI,neutral
225360.0,"ChemoCentryx shares traded higher, continuing momentum from Friday when the stock rose about 4 percent. Did not see news to justify the move higher.",2019-03-25 16:57:00-04:00,CCXI,positive
225361.0,"Benzinga's Top Upgrades, Downgrades For February 11, 2019",2019-02-11 09:10:00-05:00,CCXI,positive
225362.0,"PiperJaffray Initiates Coverage On ChemoCentryx with Overweight Rating, Announces $20 Price Target",2019-02-11 06:40:00-05:00,CCXI,negative
225363.0,Chemocentryx Announces Withdrawal Of Phase II-based Conditional Marketing Authorization Application For Anca-Associated Vasculitis In Europe; Phase III Advocate Trial Data Release Planned For Q4 2019,2019-01-24 08:35:00-05:00,CCXI,neutral
225364.0,ChemoCentryx Filing Shows Registration For $75M Common Stock Offering,2018-12-04 17:42:00-05:00,CCXI,neutral
225365.0,85 Biggest Movers From Friday,2018-11-12 05:16:00-05:00,CCXI,neutral
225366.0,"Chemocentryx Q3 EPS $(0.22) Beats $(0.24) Estimate, Sales $8.98M Miss $11.89M Estimate",2018-11-08 16:52:00-05:00,CCXI,negative
225367.0,46 Biggest Movers From Friday,2018-10-01 04:20:00-04:00,CCXI,neutral
225368.0,Mid-Afternoon Market Update: Progress Software Falls Following Mixed Q3 Results; ChemoCentryx Shares Climb,2018-09-28 14:35:00-04:00,CCXI,positive
225369.0,34 Stocks Moving In Friday's Mid-Day Session,2018-09-28 12:41:00-04:00,CCXI,neutral
225370.0,Mid-Day Market Update: Crude Oil Up 1.5%; Altimmune Shares Plunge,2018-09-28 12:02:00-04:00,CCXI,negative
225371.0,ChemoCentryx shares are up 16.2% after the company earlier withdrew its plans for a public offering of common stock.,2018-09-28 10:40:00-04:00,CCXI,positive
225372.0,Mid-Morning Market Update: Markets Edge Lower; BlackBerry Earnings Beat Expectations,2018-09-28 10:24:00-04:00,CCXI,negative
225373.0,26 Stocks Moving In Friday's Pre-Market Session,2018-09-28 08:13:00-04:00,CCXI,neutral
225374.0,51 Biggest Movers From Yesterday,2018-09-28 05:15:00-04:00,CCXI,neutral
225375.0,ChemoCentryx Withdraws Plans for Public Offering of Common Stock,2018-09-28 04:14:00-04:00,CCXI,neutral
225376.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-27 12:37:00-04:00,CCXI,neutral
225377.0,Mid-Morning Market Update: Markets Open Higher; Conagra Misses Q1 Views,2018-09-27 10:14:00-04:00,CCXI,negative
225378.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-09-27 08:10:00-04:00,CCXI,neutral
225379.0,"10 Stocks To Watch For September 27, 2018",2018-09-27 05:01:00-04:00,CCXI,neutral
225380.0,ChemoCentryx Reports $75M Common Stock Offering,2018-09-26 16:02:00-04:00,CCXI,neutral
225381.0,60 Biggest Movers From Yesterday,2018-09-19 05:08:00-04:00,CCXI,neutral
225382.0,Mid-Afternoon Market Update: Crude Oil Up 1.4%; Apogee Enterprises Shares Fall On Earnings Miss,2018-09-18 14:57:00-04:00,CCXI,negative
225383.0,44 Stocks Moving In Tuesday's Mid-Day Session,2018-09-18 12:46:00-04:00,CCXI,neutral
225384.0,Mid-Day Market Update: Dow Rises 125 Points; Twin Disc Shares Plummet,2018-09-18 12:26:00-04:00,CCXI,positive
225385.0,Vifor Pharma Group Earlier Reported Raised Equity Stake In ChemoCentryx From 6.6% To 21.2%,2018-09-18 08:18:00-04:00,CCXI,neutral
225386.0,52 Biggest Movers From Friday,2018-09-10 05:21:00-04:00,CCXI,neutral
225387.0,"B. Riley FBR Initiates Coverage On ChemoCentryx with Neutral Rating, Announces $12.50 Price Target",2018-09-07 07:15:00-04:00,CCXI,neutral
225388.0,58 Biggest Movers From Yesterday,2018-08-15 05:02:00-04:00,CCXI,neutral
225389.0,45 Stocks Moving In Tuesday's Mid-Day Session,2018-08-14 12:34:00-04:00,CCXI,neutral
225390.0,"ChemoCentryx Inc. shares are trading 8.4% lower to $11.59 after JP Morgan downgraded the company to a ""Neutral"" rating.",2018-08-14 10:04:00-04:00,CCXI,positive
225391.0,"JP Morgan Downgrades ChemoCentryx to Neutral, Raises Price Target to $15",2018-08-14 08:28:00-04:00,CCXI,positive
225392.0,"Chemocentryx Q2 EPS $(0.14) Beats $(0.15) Estimate, Sales $15.022M Beat $14.06M Estimate",2018-08-09 16:52:00-04:00,CCXI,neutral
225393.0,"Raymond James Initiates Coverage On ChemoCentryx with Strong Buy Rating, Announces $18 Price Target",2018-06-28 08:32:00-04:00,CCXI,positive
225394.0,"UPDATE: ChemoCentryx Says Vifor To Pay Co. $10M Related To Expansion Of Collaboration, License Deal To Include China",2018-06-07 16:26:00-04:00,CCXI,negative
225395.0,"UPDATE: ChemoCentryx, Vifor Entered Amendment To Collaboration, License Deal To Account For Exclusive License To Commericialize CCX140 In Certain Countries Outside US, Vifor To Pay ~$11.5M",2018-06-07 16:25:00-04:00,CCXI,positive
225396.0,"ChemoCentryx 8-K Shows Co., Vifor Fresenius Medical Care Renal Pharma Expanded Global Commercial Alliance To Provide Vifor With Commercialization Rights In CHina In Exchange For Upfront Cash Payments Of $21.5M",2018-06-07 16:23:00-04:00,CCXI,positive
225397.0,35 Stocks Moving In Monday's Mid-Day Session,2018-06-04 12:32:00-04:00,CCXI,neutral
225398.0,41 Biggest Movers From Yesterday,2018-05-17 04:32:00-04:00,CCXI,neutral
225399.0,ChemoCentryx Shares Up 7.5% After Canaccord Genuity Earlier Initiated Coverage On Stock With Buy Rating And $17 Price Target,2018-05-16 15:22:00-04:00,CCXI,positive
225400.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-05-16 12:39:00-04:00,CCXI,neutral
225401.0,"Benzinga's Top Upgrades, Downgrades For May 16, 2018",2018-05-16 09:15:00-04:00,CCXI,positive
225402.0,"Canaccord Genuity Initiates Coverage On ChemoCentryx with Buy Rating, Announces $17 Price Target",2018-05-16 06:26:00-04:00,CCXI,neutral
225403.0,"Chemocentryx Q1 EPS $(0.19) Beats $(0.25) Estimate, Sales $9.55M Beat $6.3M Estimate",2018-05-09 17:18:00-04:00,CCXI,neutral
225404.0,"Benzinga's Top Upgrades, Downgrades For May 2, 2018",2018-05-02 09:15:00-04:00,CCXI,positive
225405.0,"H.C. Wainwright Initiates Coverage On ChemoCentryx with Buy Rating, Announces $20 Price Target",2018-05-02 08:29:00-04:00,CCXI,neutral
225406.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,CCXI,neutral
225407.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,CCXI,neutral
225408.0,ChemoCentryx Shares Up 10.4% After Q4 Results,2018-03-09 12:13:00-05:00,CCXI,positive
225409.0,26 Stocks Moving In Friday's Pre-Market Session,2018-03-09 08:07:00-05:00,CCXI,neutral
225410.0,"ChemoCentryx Reports Q4 EPS $0.80 vs $(0.16) In Same Qtr. Last Year, Sales $56.301M vs $4.889M YoY",2018-03-09 07:08:00-05:00,CCXI,neutral
225411.0,"Earnings Scheduled For March 9, 2018",2018-03-09 04:25:00-05:00,CCXI,neutral
225412.0,UPDATE: ChemoCentryx Says 'Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium',2018-01-22 17:01:00-05:00,CCXI,neutral
225413.0,ChemoCentryx Reports Overall Survival Results With CCX872 For Locally Advanced/Metastatic Pancreatic Cancer: 'CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients',2018-01-22 17:00:00-05:00,CCXI,negative
225414.0,ChemoCentryx Earlier Announced Co. Has Named William Fairey COO,2018-01-08 12:50:00-05:00,CCXI,neutral
225415.0,36 Biggest Movers From Yesterday,2018-01-05 05:48:00-05:00,CCXI,neutral
225416.0,Mid-Afternoon Market Update: Dow Rises Over 150 Points; L Brands Shares Plunge,2018-01-04 14:31:00-05:00,CCXI,positive
225417.0,Mid-Day Market Update: Buckle Drops After December Sales Results; ChemoCentryx Shares Spike Higher,2018-01-04 12:41:00-05:00,CCXI,positive
225418.0,33 Stocks Moving In Thursday's Mid-Day Session,2018-01-04 12:25:00-05:00,CCXI,neutral
225419.0,Mid-Morning Market Update: Markets Open Higher; Walgreens Earnings Top Views,2018-01-04 10:53:00-05:00,CCXI,positive
225420.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-01-04 08:27:00-05:00,CCXI,neutral
225421.0,UPDATE: ChemoCentryx Entered $50M 'Growth Capital Financing Agreement with Hercules Capital',2018-01-04 07:08:00-05:00,CCXI,positive
225422.0,UPDATE: ChemoCentryx Says Will 'Receive $50M Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis',2018-01-04 07:07:00-05:00,CCXI,neutral
225423.0,ChemoCentryx Reports Securing Of Up To $100M In New Capital Commitments,2018-01-04 07:07:00-05:00,CCXI,positive
225424.0,ChemoCentryx Announces EMA has Accepted for Review the Registration Dossier in Support of Conditional Marketing Authorization for Avacopan in the Treatment of Patients with ANCA-Associated Vasculitis,2018-01-04 03:58:00-05:00,CCXI,positive
225425.0,"ChemoCentryx Reports Q3 EPS $(0.13) vs $(0.15) In Same Qtr. Last Year, Sales $9.029M vs $9.03M Est.",2017-11-07 16:50:00-05:00,CCXI,neutral
225426.0,20 Stocks Moving In Friday's Pre-Market Session,2017-09-01 08:02:00-04:00,CCXI,neutral
225427.0,"ChemoCentryx Reports Q2 Loss/Share $(0.19) vs. $(0.17) Est., Sales $8.9M vs. $8.5M Est.",2017-08-08 16:27:00-04:00,CCXI,neutral
225428.0,ChemoCentryx Receives EU Orphan Designation For Avacopan,2017-06-28 10:45:00-04:00,CCXI,neutral
225429.0,UPDATE: ChemoCentryx Says 'Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgAN,2017-06-06 07:34:00-04:00,CCXI,negative
225430.0,"ChemoCentryx Reports Oral Presentations at ERA-EDTA Congress Showed Fourth Potential Indication for Avacopan, Potential for CCR2 Inhibition in FSGS",2017-06-06 07:34:00-04:00,CCXI,negative
225431.0,ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy,2017-05-23 08:30:00-04:00,CCXI,positive
225432.0,"ChemoCentryx Reports Q1 EPS $(0.12) vs $(0.26) Est., Sales $8.23M vs $5.3M Est.",2017-05-10 16:16:00-04:00,CCXI,neutral
225433.0,ChemoCentryx Reports Received FDA Orphan Drug Designation for Avacopan for Treatment of C3G,2017-03-22 08:30:00-04:00,CCXI,neutral
225434.0,"ChemoCentryx Reports Q4 EPS $(0.16) vs $(0.22) Est., Sales $4.889M vs $3.3M Est.",2017-03-14 16:09:00-04:00,CCXI,neutral
225435.0,UPDATE: ChemoCentryx Will Receive Added $20M Upfront Cash Commitment Plus Royalties on Potential Net Sales,2017-02-14 07:05:00-05:00,CCXI,positive
225436.0,"Galenica's Vifor Pharma, ChemoCentryx Report Expansion of Avacopan Deal for Rare Renal Diseases",2017-02-14 07:04:00-05:00,CCXI,neutral
225437.0,ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer,2017-01-20 15:32:00-05:00,CCXI,negative
225438.0,"ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases",2016-12-22 13:59:00-05:00,CCXI,positive
225439.0,"ChemoCentryx Shares Resume Trade, Turn Positive, Now Up 9%",2016-12-22 13:00:00-05:00,CCXI,positive
225440.0,ChemoCentryx Shares to Resume Trade at 1 p.m. EST,2016-12-22 12:40:00-05:00,CCXI,positive
225441.0,"Vifor Pharma, ChemoCentryx Announces Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases, Will Receive Upfront $50M Cash Commitment Plus Possible Milestones, Royalties",2016-12-22 12:31:00-05:00,CCXI,positive
225442.0,ChemoCentryx Shares Halted News Pending,2016-12-22 12:25:00-05:00,CCXI,positive
225443.0,American Soceity Of Nephrology (ASN) Kidney Week Taking Place In Chicago,2016-11-17 10:24:00-05:00,CCXI,neutral
225444.0,25 Stocks Moving In Wednesday's Pre-Market Session,2016-11-09 08:28:00-05:00,CCXI,neutral
225445.0,"ChemoCentryx Reports Q3 EPS $(0.15) vs. Est. $(0.08), Rev. $4.25M vs. Est. $1.2M",2016-11-07 16:14:00-05:00,CCXI,neutral
225446.0,ChemoCentryx Reports CCX872 Shown to Reduce Liver Fibrosis in NASH Models,2016-10-18 08:33:00-04:00,CCXI,neutral
225447.0,ChemoCentryx Reports Data from Ongoing Pilot Phase II Trial of CCX168 in aHUS: 'Treatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation',2016-10-17 08:32:00-04:00,CCXI,positive
225448.0,"15 Stocks That Rallied 4 Days, Then Sold Off Yesterday",2016-09-29 07:13:00-04:00,CCXI,neutral
225449.0,ChemoCentryx Shares Up 9.87% On Mid-Morning Trading,2016-09-27 10:21:00-04:00,CCXI,positive
225450.0,Mid-Afternoon Market Update: Accuride Jumps Following Acquisition Announcement; Lululemon Shares Slide,2016-09-02 14:43:00-04:00,CCXI,positive
225451.0,10 Biggest Mid-Day Losers For Friday,2016-09-02 13:04:00-04:00,CCXI,negative
225452.0,Mid-Day Market Update: Crude Oil Up 3%; VeriFone Shares Decline On Lowered Forecast,2016-09-02 12:10:00-04:00,CCXI,negative
225453.0,Mid-Morning Market Update: Markets Open Higher; Lululemon Sales Miss Views,2016-09-02 10:06:00-04:00,CCXI,negative
225454.0,ChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer,2016-09-01 16:06:00-04:00,CCXI,negative
225455.0,"After-Hours Gainers Aug. 8, 2016: HIIQ Up 36%, REN 20%, CCXI 14.4%, FH 14.3%, FGEN 10.4%, AMPH 9.4%, CSLT 8.9%, NVRO 8.7%, ENDP 7.5%",2016-08-08 18:58:00-04:00,CCXI,neutral
225456.0,"ChemoCentryx Reports Q2 EPS $(0.22) vs. Est. $0.07, Rev. $2.7M Does Not Compare To $19.2M",2016-08-08 17:09:00-04:00,CCXI,neutral
225457.0,ChemoCentryx Reports Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development,2016-06-16 08:31:00-04:00,CCXI,positive
225458.0,ChemoCentryx Reports Received EMA PRIME Designation for Accelerated Assessment of CCX168 for Treatment of Patients with ANCA-Associated Vasculitis,2016-06-01 08:32:00-04:00,CCXI,neutral
225459.0,ChemoCentryx Reports Phase II Clear Trial Met Primary Endpoint,2016-05-23 09:16:00-04:00,CCXI,positive
225460.0,Midday Gainers In Depth,2016-05-18 13:10:00-04:00,CCXI,neutral
225461.0,"Director Edwards Buys 25,000 Shares of ChemoCentryx @$4.05/Share -Form 4",2016-05-17 04:34:00-04:00,CCXI,positive
225462.0,ChemoCentryx Spikes to High of $4.29 on Vol; Insider Buy of 40K Shares Reported Late Fri,2016-05-16 11:15:00-04:00,CCXI,positive
225463.0,"Dir Parker Buys 40,000 Shares of ChemoCentryx @$4.03/Share -Form 4",2016-05-13 16:09:00-04:00,CCXI,positive
225464.0,ChemoCentryx Inc Shares Up 50.50% On The Day At $4.46/Share,2016-05-11 13:18:00-04:00,CCXI,positive
225465.0,Mid-Afternoon Market Update: Dow Jumps Over 200 Points; SolarCity Shares Tumble,2016-05-10 15:45:00-04:00,CCXI,positive
225466.0,Mid-Day Market Update: Sodastream Gains Following Earnings Beat; NewLink Genetics Shares Decline,2016-05-10 12:14:00-04:00,CCXI,positive
225467.0,Mid-Morning Market Update: Markets Open Higher; Allergan Earnings Top Views,2016-05-10 10:10:00-04:00,CCXI,positive
225468.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-05-10 08:28:00-04:00,CCXI,neutral
225469.0,UPDATE: ChemoCentryx Now +109% Premarket @$4.40 Following US Press Release Announcing Licence Agreement for  CCX168,2016-05-10 07:18:00-04:00,CCXI,positive
225470.0,"ChemoCentryx Reports Q1 Loss $15.2M, EPS $(0.34) vs $(0.27) Est.",2016-05-10 07:05:00-04:00,CCXI,negative
225471.0,ChemoCentryx +90% Premarket @$4.00 Following Announcement of Licence Agreement for  CCX168,2016-05-10 05:34:00-04:00,CCXI,positive
225472.0,"Vifor Pharma Licenses Marketing Rights to ChemoCentryx's CCX168 in Europe, Canada, Mexico, Central and S. America, S. Korea; ChemoCentryx to Receive Upfront Payment of $60M, Equity Investment of $25M @$7.50/Share",2016-05-10 04:35:00-04:00,CCXI,neutral
225473.0,ChemoCentryx Reports Received FDA Orphan Products Development Grant for Orally-Administered Complement CCX168 for Treatment of ANCA-Associated Vasculitits,2016-04-28 08:38:00-04:00,CCXI,positive
225474.0,Chemocentryx Files For Mix Shelf Up To $150M,2016-04-13 16:48:00-04:00,CCXI,neutral
225475.0,ChemoCentryx Reports Q4 Earnings $(11.6M) vs $(12.2M) in Same Qtr. Last Year,2016-03-14 16:10:00-04:00,CCXI,neutral
225476.0,"UPDATE: ChemoCentryx Says Primary Endpoint Achieved, CCX168 Appears Safe, Well Tolerated",2016-01-06 07:10:00-05:00,CCXI,positive
225477.0,ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168,2016-01-06 07:00:00-05:00,CCXI,positive
225478.0,Chemocentryx Reports Q3 EPS $(0.26) vs $(0.29) Est.,2015-11-09 17:10:00-05:00,CCXI,neutral
225479.0,ChemoCentryx Announces Immuno-Oncology Data Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting,2015-11-04 08:33:00-05:00,CCXI,negative
225480.0,Wednesday's After-Hours Movers: 10 Stocks To Watch,2015-09-24 08:10:00-04:00,CCXI,neutral
225481.0,ChemoCentryx Reports Q2 Loss $0.28 Vs Est Loss $0.29,2015-08-06 17:35:00-04:00,CCXI,negative
225482.0,Encouraging Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2 Inhibitor CCX140 Highlighted at the 52nd ERA-EDTA Congress,2015-05-29 07:01:00-04:00,CCXI,positive
225483.0,Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Showcased at the 52nd Annual ERA-EDTA Congress,2015-05-26 08:31:00-04:00,CCXI,positive
225484.0,"JP Morgan Upgrades Chemocentryx to Overweight, Raises PT to $14.00",2015-05-18 05:25:00-04:00,CCXI,neutral
225485.0,"Chemocentryx Reports Q1 Loss of $0.28/Share, Inline",2015-05-06 16:52:00-04:00,CCXI,negative
225486.0,"ChemoCentryx Begins Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, in Pancreatic Cancer",2015-04-20 08:02:00-04:00,CCXI,negative
225487.0,ChemoCenryx Reports Inline Q4 EPS -$0.28,2015-03-12 16:06:00-04:00,CCXI,neutral
225488.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,CCXI,neutral
225489.0,"Biggest Gainers From Friday, December 12, 2014",2014-12-12 16:31:00-05:00,CCXI,neutral
225490.0,Mid-Morning Market Update: Markets Open Lower; Adobe Earnings Top Expectations,2014-12-12 11:34:00-05:00,CCXI,negative
225491.0,2 Stocks With Trending Social Sentiment Today,2014-12-12 11:02:00-05:00,CCXI,neutral
225492.0,"ChemoCentryx Up 70%, Lead Drug Meets Phase II Objective",2014-12-12 10:37:00-05:00,CCXI,neutral
225493.0,Morning Market Movers,2014-12-12 09:42:00-05:00,CCXI,neutral
225494.0,Benzinga's Top #PreMarket Gainers,2014-12-12 08:07:00-05:00,CCXI,positive
225495.0,ChemoCentryx Shares Rise 100% Premarket as Primary Endpoint Achieved in Phase II CCX140 Trial,2014-12-12 08:02:00-05:00,CCXI,positive
225496.0,ChemoCentryx Reports Positive Phase II Diabetic,2014-12-12 06:33:00-05:00,CCXI,positive
225497.0,ChemoCentryx Announces Primary Endpoint Achieved in Phase II CCX140 Trial,2014-12-12 06:33:00-05:00,CCXI,neutral
225498.0,ChemoCentryx Granted EU Orphan Drug Designation For CCX168,2014-12-04 08:31:00-05:00,CCXI,positive
225499.0,ChemoCentryx Inc's CCX168 Granted Orphan-Drug Designation,2014-11-20 16:31:00-05:00,CCXI,positive
225500.0,"ChemoCentryx, Inc. Reports Q3 EPS of $(0.25) vs $(0.28) Est",2014-11-05 16:49:00-05:00,CCXI,neutral
225501.0,"ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study ",2014-10-21 09:03:00-04:00,CCXI,positive
225502.0,ChemoCentryx's CCR9 Inhibitor Shown to Be Well Tolerated for Treatment of Inflammatory Bowel Diseases,2014-10-21 08:34:00-04:00,CCXI,positive
225503.0,ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease,2014-10-20 08:32:00-04:00,CCXI,neutral
225504.0,"Option Alert: Chemocentryx Shares Spike Higher; 1,000 Feb $5 Calls Traded at Ask @$1.10; Currently $4.76",2014-09-30 10:53:00-04:00,CCXI,positive
225505.0,ChemoCentryx's CCX168 Granted FDA Orphan-Drug Designation in ANCA-Associated Diseases ,2014-06-03 07:07:00-04:00,CCXI,positive
225506.0,"ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements ",2014-06-02 05:46:00-04:00,CCXI,positive
225507.0,"ChemoCentryx, Inc. Reports Q1 EPS of $(0.27)",2014-05-08 16:08:00-04:00,CCXI,neutral
225508.0,"ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology",2014-03-27 08:31:00-04:00,CCXI,neutral
225509.0,Benzinga's Top #PreMarket Gainers,2013-12-04 08:11:00-05:00,CCXI,positive
225510.0,"Citigroup Downgrades ChemoCentryx, Inc. to Neutral",2013-12-04 07:34:00-05:00,CCXI,neutral
225511.0,"ChemoCentryx Reports Positive Top-Line Results of CCX168 Phase I Data, Shows Appears to Be Safe",2013-12-03 16:09:00-05:00,CCXI,positive
225512.0,"ChemoCentryx, Inc. Reports Q3 EPS of $(0.22) vs $(0.26) Est; Revenue of $1.52M vs $1.97M Est",2013-11-07 16:59:00-05:00,CCXI,neutral
225513.0,"ChemoCentryx Will Regain Global Rights for Vercirnon from Glaxo, Will Assess If Drug Maintains Remission in Crohn's Disease",2013-09-18 08:39:00-04:00,CCXI,neutral
225514.0,GlaxoSmithKline Terminates Crohn's Drug Program Following ChemoCentryx Trial Failure -FierceBiotech,2013-09-17 11:49:00-04:00,CCXI,negative
225515.0,"JP Morgan Downgrades ChemoCentryx, Inc. to Neutral",2013-09-10 10:37:00-04:00,CCXI,positive
225516.0,Morning Market Losers ,2013-09-10 10:24:00-04:00,CCXI,negative
225517.0,Benzinga's Top Pre-Market Losers,2013-09-10 08:14:00-04:00,CCXI,negative
225518.0,US Stock Futures Up After Upbeat China Data,2013-09-10 07:08:00-04:00,CCXI,neutral
225519.0,"ChemoCentryx Issues Top-Line Interim Results for CCX140, Says Data Showed Statistically Significant Reduction in Protein",2013-09-10 07:03:00-04:00,CCXI,positive
225520.0,"Shares of ChemoCentryx Resume Trade, Now Down 40+%",2013-08-23 10:06:00-04:00,CCXI,positive
225521.0,"Shares of ChemoCentryx Halted on LULD Trading Pause, Stock is Down 30.7%",2013-08-23 10:01:00-04:00,CCXI,positive
225522.0,"Shares of ChemoCentryx Resume Trade, Down 28%",2013-08-23 09:55:00-04:00,CCXI,positive
225523.0,ChemoCentryx Shares to Resume Trade at 9:55AM EDT,2013-08-23 09:30:00-04:00,CCXI,positive
225524.0,ChemoCentryx Says Glaxo's Top-Line Results from SHIELD-1 Phase III Study of Vercirnon Did Not Meet Primary Endpoint,2013-08-23 09:25:00-04:00,CCXI,neutral
225525.0,ChemoCentryx Shares Halted News Pending,2013-08-23 09:15:00-04:00,CCXI,positive
225526.0,"ChemoCentryx, Inc. Reports Q2 EPS of $(0.23) vs $(0.28) Est",2013-08-12 16:06:00-04:00,CCXI,neutral
225527.0,"ChemoCentryx Announces Appointment of Health Care Insurance Executive Ira Klein, MD, to Company's Board of Directors",2013-05-28 16:07:00-04:00,CCXI,positive
225528.0,UPDATE: Stifel Nicolaus Raises PT on ChemoCentryx Following R&D Day,2013-05-20 09:08:00-04:00,CCXI,neutral
225529.0,"Stifel Nicolaus Maintains Buy on ChemoCentryx, Inc., Raises PT to $20.00",2013-05-20 08:22:00-04:00,CCXI,neutral
225530.0,J.P. Morgan Reiterates Neutral Rating on ChemoCentryx Following Analyst Day,2013-05-17 11:37:00-04:00,CCXI,neutral
225531.0,"ChemoCentryx, Inc. Reports Q1 EPS of $(0.28) vs $(0.27) Est",2013-05-13 16:17:00-04:00,CCXI,neutral
225532.0,"Earnings Scheduled For May 13, 2013 ",2013-05-13 04:34:00-04:00,CCXI,neutral
225533.0,ChemoCentryx Closes Follow-On Offering of 5M Shares at $12/Share,2013-04-22 16:15:00-04:00,CCXI,positive
225534.0,ChemoCentryx Prices 5M Share Offering at $12.00/Share,2013-04-17 06:02:00-04:00,CCXI,positive
225535.0,ChemoCentryx Files $150M Mixed Securities Shelf,2013-03-20 16:19:00-04:00,CCXI,positive
225536.0,ChemoCentryx Files $150M Mixed Securities Shelf,2013-03-20 16:19:00-04:00,CCXI,positive
225537.0,"ChemoCentryx, Inc. Reports Q4 EPS of $(0.28), Inline",2013-03-13 16:15:00-04:00,CCXI,neutral
225538.0,"Earnings Scheduled For March 13, 2013",2013-03-13 04:21:00-04:00,CCXI,neutral
225539.0,ChemoCentryx Announces Initiation of Phase I Clinical Trial for CCX507,2013-01-07 07:14:00-05:00,CCXI,neutral
225540.0,UPDATE: Stifel Nicolaus Initiates Buy on ChemoCentryx on Potential of Lead Drug Candidate  ,2012-11-14 11:21:00-05:00,CCXI,neutral
225541.0,"Stifel Nicolaus Initiates Coverage on Chemocentryx at Buy, Announces PT of $16",2012-11-14 08:12:00-05:00,CCXI,neutral
225542.0,From Earlier: ChemoCentryx Reports Data for CCX872,2012-10-02 09:17:00-04:00,CCXI,neutral
225543.0,"ChemoCentryx Announces Peer-Reviewed Publication of Positive Phase 2 Clinical Data with CCX354, a Novel Inhibitor of Chemokine Receptor CCR1 in Patients with Rheumatoid Arthritis ",2012-06-08 07:00:00-04:00,CCXI,positive
225544.0,ChemoCentryx Reports Q1 EPS $(0.28) vs $(0.21) Est,2012-05-10 08:42:00-04:00,CCXI,neutral
225545.0,"JP Morgan Initiates Coverage on Chemocentryx at Overweight, Announces PT of $16",2012-03-19 07:11:00-04:00,CCXI,neutral
225546.0,"ChemoCentryx IPO Opens for Trading at $10.32, after Originally Pricing at $10.00/Share",2012-02-08 11:00:00-05:00,CCXI,neutral
225547.0,ChemoCentryx Prices Initial Public Offering of 4.5M Shares at $10,2012-02-08 09:15:00-05:00,CCXI,positive
